CO2023001072A2 - Vacuna combinada de sars-cov-2 e influenza - Google Patents

Vacuna combinada de sars-cov-2 e influenza

Info

Publication number
CO2023001072A2
CO2023001072A2 CONC2023/0001072A CO2023001072A CO2023001072A2 CO 2023001072 A2 CO2023001072 A2 CO 2023001072A2 CO 2023001072 A CO2023001072 A CO 2023001072A CO 2023001072 A2 CO2023001072 A2 CO 2023001072A2
Authority
CO
Colombia
Prior art keywords
cov
sars
combined
antigens
vaccines
Prior art date
Application number
CONC2023/0001072A
Other languages
English (en)
Inventor
Reinhard Glück
Agata Fazzio
Emanuele Montomoli
Kaspar Bänziger
Carlos Quinto
Original Assignee
Spicona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spicona Inc filed Critical Spicona Inc
Publication of CO2023001072A2 publication Critical patent/CO2023001072A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a vacunas combinadas tanto contra la influenza como contra la COVID–19. En particular, la invención se refiere a vacunas combinadas que comprenden uno o más antígenos del virus de la influenza y uno o más antígenos del SARS–CoV–2 (coronavirus SARS–CoV–2), particularmente uno o más antígenos de la proteína espiga del SARS–CoV–2, así como vacunas que comprenden polinucleótidos que codifican dichos antígenos, y tales vacunas para el tratamiento o la prevención de la COVID–19 (infección por SARS–CoV–2) e infección por influenza.
CONC2023/0001072A 2020-07-07 2023-01-31 Vacuna combinada de sars-cov-2 e influenza CO2023001072A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2010425.3A GB2596820A (en) 2020-07-07 2020-07-07 Combination vaccine
PCT/IB2021/056102 WO2022009121A1 (en) 2020-07-07 2021-07-07 Sars-cov-2 and influenza combination vaccine

Publications (1)

Publication Number Publication Date
CO2023001072A2 true CO2023001072A2 (es) 2023-06-20

Family

ID=72050416

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0001072A CO2023001072A2 (es) 2020-07-07 2023-01-31 Vacuna combinada de sars-cov-2 e influenza

Country Status (15)

Country Link
US (1) US20230256085A1 (es)
EP (1) EP4178612A1 (es)
JP (1) JP2023533772A (es)
KR (1) KR20230049084A (es)
CN (1) CN117957016A (es)
AR (1) AR122899A1 (es)
AU (1) AU2021303789A1 (es)
BR (1) BR112023000323A2 (es)
CA (1) CA3184878A1 (es)
CO (1) CO2023001072A2 (es)
GB (1) GB2596820A (es)
IL (1) IL299735A (es)
MX (1) MX2023000411A (es)
TW (1) TW202207979A (es)
WO (1) WO2022009121A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
CN113521268A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
CN113293145B (zh) * 2021-02-01 2022-08-26 上海青赛生物科技有限公司 一种麻疹病毒活载体新冠疫苗
WO2022221440A1 (en) * 2021-04-14 2022-10-20 Modernatx, Inc. Influenza-coronavirus combination vaccines
CN113462700B (zh) * 2021-05-07 2023-06-09 杨光华 SARS-CoV-2线性DNA疫苗
CN114717251B (zh) * 2021-08-24 2023-03-24 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2原始株和Beta株的腺病毒载体疫苗
CN113755644B (zh) * 2021-09-24 2024-05-03 中国科学院武汉病毒研究所 一种检测新型冠状病毒Alpha和Delta突变体试剂盒及应用
WO2023047419A1 (en) * 2021-09-24 2023-03-30 Bharat Biotech International Limited A vaccine for coronavirus and influenza virus, and method for preparation thereof
CN114891817A (zh) * 2022-04-15 2022-08-12 华南理工大学 一种多聚肽及其制备方法与应用
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN115992101B (zh) * 2023-03-22 2023-07-28 深圳市卫光生物制品股份有限公司 一种流感病毒裂解疫苗原液的制备方法
CN116350769A (zh) * 2023-03-31 2023-06-30 北京吉诺卫生物科技有限公司 一种新冠病毒和流感病毒的联合疫苗、其制备方法与应用
CN116327910B (zh) * 2023-03-31 2024-05-03 北京吉诺卫生物科技有限公司 一种新冠病毒、流感病毒和/或rsv的联合疫苗、其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
CN1775287A (zh) * 2004-11-16 2006-05-24 北京科兴生物制品有限公司 一种sars流感二价联合疫苗及其制备工艺
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
US20130236494A1 (en) * 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
CN107961371B (zh) * 2017-04-19 2020-08-11 武汉博沃生物科技有限公司 季节流感-rsv联合疫苗及其制备方法和应用
CN110974950B (zh) * 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
CN111217917B (zh) * 2020-02-26 2020-10-23 康希诺生物股份公司 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法
CN111218458B (zh) * 2020-02-27 2020-11-20 珠海丽凡达生物技术有限公司 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法

Also Published As

Publication number Publication date
WO2022009121A1 (en) 2022-01-13
AR122899A1 (es) 2022-10-12
IL299735A (en) 2023-03-01
AU2021303789A1 (en) 2023-02-16
CN117957016A (zh) 2024-04-30
GB202010425D0 (en) 2020-08-19
TW202207979A (zh) 2022-03-01
US20230256085A1 (en) 2023-08-17
MX2023000411A (es) 2023-04-10
CA3184878A1 (en) 2022-01-13
EP4178612A1 (en) 2023-05-17
BR112023000323A2 (pt) 2023-01-31
GB2596820A (en) 2022-01-12
JP2023533772A (ja) 2023-08-04
KR20230049084A (ko) 2023-04-12

Similar Documents

Publication Publication Date Title
CO2023001072A2 (es) Vacuna combinada de sars-cov-2 e influenza
AR121361A1 (es) Vacuna
CO2019001379A2 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih .
ECSP17077930A (es) Métodos y kits para tratar la depresión
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
UY32457A (es) Vacuna del virus del dengue inactivado
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
CO6531435A2 (es) Nuevas formulaciones de vacuna que comprende adyuvantes que contienen saponina
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
ECSP21042554A (es) Proteínas f de prefusión del vrs estabilizadas
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
CL2018003383A1 (es) Proteínas f de prefusión del vrs estabilizadas.
CL2023000699A1 (es) Tratamientos de angioedema
AR101814A1 (es) Partícula de tipo virus flavivirus
BR112019003126A2 (pt) método de tratamento ou prevenção de diarreia epidêmica suína, vacina e kit de vacinas
BR112023005043A2 (pt) Vacina contra covid-19 à base de piv5
BR112018015696A2 (pt) composições e métodos para gerar uma resposta imune para um flavivírus
BR112018010679A8 (pt) métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
BR112022016891A2 (pt) Vacina contra a infecção por vírus da peste suína africana
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae